Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

521. Fully intermittent dosing with drugs for treating tuberculosis in adults.

Fully intermittent dosing with drugs for treating tuberculosis in adults. BACKGROUND: The number of people infected with tuberculosis continues to rise worldwide. Rifampicin-containing treatment regimens can achieve high cure rates. Intermittent drug treatment delivered in the community has the potential to improve adherence to treatment. OBJECTIVES: The objective of this review was to compare the effectiveness of rifampicin-containing short-course chemotherapy regimens, given two or three (...) times a week, with similar regimens given daily in adult patients with pulmonary tuberculosis. SEARCH STRATEGY: We searched the Cochrane Infectious Diseases Group specialized trials register, The Cochrane Controlled Trials Register, MEDLINE, and reference lists of articles. We contacted experts in the field. SELECTION CRITERIA: Randomized and quasi-randomized trials of any multiple drug regimen containing rifampicin in patients with confirmed pulmonary tuberculosis. Treatment had to be given up

Cochrane2001

522. Mycobacterium vaccae immunotherapy for treating tuberculosis.

Mycobacterium vaccae immunotherapy for treating tuberculosis. BACKGROUND: Some authorities have advocated Mycobacterium vaccae immunotherapy for treating tuberculosis and other infections caused by mycobacteria. OBJECTIVES: To assess the effects of Mycobacterium vaccae as an adjunct to chemotherapy for treating tuberculosis. SEARCH STRATEGY: We searched the Cochrane Infectious Diseases Group trials register, the Cochrane Controlled Trials register, Medline, Embase and reference lists (...) of articles. We also contacted organisations and individuals working in the field. SELECTION CRITERIA: Randomised and quasi-randomised trials using whole, killed Mycobacterium vaccae for patients with tuberculosis. DATA COLLECTION AND ANALYSIS: One reviewer assessed trial quality and extracted data. MAIN RESULTS: Six trials met the inclusion criteria. There was no effect on mortality (three trials, OR 1.01, 95% CI 0.51 to 1.99). No consistent effect on sputum negativity or sputum culture was shown. Most

Cochrane2001

523. Directly observed therapy for treating tuberculosis.

Directly observed therapy for treating tuberculosis. BACKGROUND: Up to half the people with tuberculosis do not complete their treatment. Strategies to improve adherence to diagnostic and treatment regimens are therefore important. OBJECTIVES: To assess the effects of directly observed therapy by an appointed agent (health worker, community volunteer, or family member) on cure and treatment completion in people on treatment for tuberculosis. SEARCH STRATEGY: We searched The Cochrane Controlled (...) Trials Register, the Cochrane Infectious Diseases Group specialized trials register, MEDLINE, EMBASE, LILACS, and reference lists of articles. We also contacted experts in the field. SELECTION CRITERIA: Randomized and quasi-randomized trials of direct observation of tablet swallowing compared with self treatment for tuberculosis. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trial quality and extracted data. MAIN RESULTS: Four studies (n = 1603 participants) included

Cochrane2001

524. Report on the second interregional meeting of the maghreb tuberculosis control initiative. Rabat, Morocco, 4-6 May 2000

Report on the second interregional meeting of the maghreb tuberculosis control initiative. Rabat, Morocco, 4-6 May 2000 WHO IRIS: Report on the second interregional meeting of the maghreb tuberculosis control initiative. Rabat, Morocco, 4-6 May 2000 Browse Related links Files in This Item: File Description Size Format 719.64 kB Adobe PDF Title: Report on the second interregional meeting of the maghreb tuberculosis control initiative. Rabat, Morocco, 4-6 May 2000 Authors: Issue Date: 2001

WHO2001

525. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations

Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations Dasgupta K, Schwartzman K, Marchand R, Tennenbaum T N, Brassard P, Menzies D Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The screening of close contacts and immigrant populations for tuberculosis (TB). Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The study population consisted of immigration applicants undergoing radiographic screening, already

NHS Economic Evaluation Database.2000

526. Antepartum or postpartum isoniazid treatment of latent tuberculosis infection

Antepartum or postpartum isoniazid treatment of latent tuberculosis infection Antepartum or postpartum isoniazid treatment of latent tuberculosis infection Antepartum or postpartum isoniazid treatment of latent tuberculosis infection Boggess K A, Myers E R, Hamilton C D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology Three strategies for treating latent tuberculosis (TB) in pregnant women aged less than 35 years were examined. The treatment options were antepartum isoniazid (300 mg/day isoniazid with pyridoxine beginning at 20 weeks' gestation for 6 months), postpartum isoniazid (300 mg/day isoniazid with pyridoxine for 6 months after delivery) and no treatment. Type of intervention Treatment. Economic study type Cost

NHS Economic Evaluation Database.2000

527. Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis

Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence (...) of previous tuberculosis: an outcome and cost-effectiveness analysis Jasmer R M, Snyder D C, Chin D P, Hopewell P C, Cuthbert S S, Paz E A, Daley C L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Isoniazid (ISO) was compared

NHS Economic Evaluation Database.2000

528. An incremental cost-effectiveness analysis of the first, second and third sputum examination in the diagnosis of pulmonary tuberculosis

An incremental cost-effectiveness analysis of the first, second and third sputum examination in the diagnosis of pulmonary tuberculosis An incremental cost-effectiveness analysis of the first, second and third sputum examination in the diagnosis of pulmonary tuberculosis An incremental cost-effectiveness analysis of the first, second and third sputum examination in the diagnosis of pulmonary tuberculosis Walker D, McNerney R, Mwembo M K, Foster S, Tihon V, Godfrey-Faussett P Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The examination of three, consecutive sputum smears for the diagnosis of pulmonary tuberculosis (TB). Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population The study

NHS Economic Evaluation Database.2000

529. Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings

Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings Yoshiyama T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of isoniazid as preventative therapy for those who have had contact with tuberculosis (TB) patients. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised Japanese men and women, stratified according

NHS Economic Evaluation Database.2000

530. The cost-effectiveness of evidence-based guidelines and practice for screening and prevention of tuberculosis

The cost-effectiveness of evidence-based guidelines and practice for screening and prevention of tuberculosis The cost-effectiveness of evidence-based guidelines and practice for screening and prevention of tuberculosis The cost-effectiveness of evidence-based guidelines and practice for screening and prevention of tuberculosis MacIntyre C R, Plant A J, Hendrie D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Contact tracing through the use of skin test or mass chest radiographs (CXR) in the detection of tuberculosis (TB). Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The study population was made up of people who had come into contact with a case of infectious TB (about

NHS Economic Evaluation Database.2000

531. The cost-effectiveness of screening for latent tuberculosis infection

The cost-effectiveness of screening for latent tuberculosis infection The cost-effectiveness of screening for latent tuberculosis infection The cost-effectiveness of screening for latent tuberculosis infection Taylor Z Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology The technology studied was the screening for latent tuberculosis infection (LTBI), and its treatment with isoniazid. Isoniazid is a common treatment for patients under 35 years of age with a positive tuberculin test. Type of intervention Screening and treatment. Economic study type Cost-utility analysis. Study population The study population comprised patients suffering from LTBI. Setting The setting was the community. The study was carried out in Atlanta, GA, USA

NHS Economic Evaluation Database.2000

532. Tuberculosis screening of immigrants to low-prevalence countries: a cost-effectiveness analysis

Tuberculosis screening of immigrants to low-prevalence countries: a cost-effectiveness analysis Tuberculosis screening of immigrants to low-prevalence countries: a cost-effectiveness analysis Tuberculosis screening of immigrants to low-prevalence countries: a cost-effectiveness analysis Schwartzman K, Menzies D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Tuberculosis screening of immigrants to low-prevalence countries. Type of intervention Screening and primary prevention. Economic study type Cost-effectiveness analysis. Study population A hypothetical population of 20-year-old immigrants. Setting Hospital. The economic study was carried out in Canada. Dates to which data relate Effectiveness data were collected from studies

NHS Economic Evaluation Database.2000

533. Cost effectiveness of DOTS and non-DOTS strategies for smear-positive pulmonary tuberculosis in Beijing

Cost effectiveness of DOTS and non-DOTS strategies for smear-positive pulmonary tuberculosis in Beijing Cost effectiveness of DOTS and non-DOTS strategies for smear-positive pulmonary tuberculosis in Beijing Cost effectiveness of DOTS and non-DOTS strategies for smear-positive pulmonary tuberculosis in Beijing Xu Q, Jin S G, Zhang L X Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Chemotherapy by directly observed treatment, short course (DOTS), as part of a tuberculosis (TB) control programme for patients with sputum smear-positive TB, was examined. The strategy consisted of treating detected cases for 7 months initially, 8 months for retreated cases, 1.5 years for patients with multidrug resistance (MDR), and 5 years

NHS Economic Evaluation Database.2000

534. The rapid diagnosis of smear-negative pulmonary tuberculosis: a cost-effectiveness analysis

The rapid diagnosis of smear-negative pulmonary tuberculosis: a cost-effectiveness analysis The rapid diagnosis of smear-negative pulmonary tuberculosis: a cost-effectiveness analysis The rapid diagnosis of smear-negative pulmonary tuberculosis: a cost-effectiveness analysis Lim T K, Cherian J, Poh K L, Leong T Y Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health interventions examined in the study were six strategies for the rapid diagnosis of smear-negative pulmonary tuberculosis (PTB): bronchoalveolar lavage (BAL) + nucleid acid amplification tests (NNA): performing nucleic acid amplification test for Mycobacterium tuberculosis on specimens obtained from the respiratory tract by BAL; empirical strategy: relying

NHS Economic Evaluation Database.2000

537. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O

Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O 10732934 2000 03 30 2000 03 30 2016 10 17 0098-7484 283 11 2000 Mar 15 JAMA JAMA Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs (...) for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. 1445-50 Because of problems with adherence, toxicity, and increasing resistance associated with 6- to 12-month isoniazid regimens, an alternative short-course tuberculosis preventive regimen is needed. To compare a 2-month regimen of daily rifampin and pyrazinamide with a 12-month regimen of daily isoniazid in preventing tuberculosis

JAMA2000

538. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial.

Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. 11081529 2000 11 17 2000 11 30 2015 06 16 0140-6736 356 9240 2000 Oct 28 Lancet (London, England) Lancet Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. 1470-4 Patients with HIV-1 infection respond well to treatment for active tuberculosis, but whether such patients are at increased risk (...) of disease recurrence after complete cure is uncertain. We did a randomised trial in Port au Prince, Haiti, to determine whether recurrent tuberculosis after curative tuberculosis treatment is more common in HIV-1-infected individuals than HIV-1-uninfected individuals, and to determine whether post-treatment isoniazid prophylaxis decreases the risk of recurrent tuberculosis. Patients older than 18 years who were diagnosed with a first episode of tuberculosis at the national HIV testing centre in Haiti

Lancet2000

539. Drugs for preventing tuberculosis in HIV infected persons.

Drugs for preventing tuberculosis in HIV infected persons. BACKGROUND: People with HIV have a increased risk of developing tuberculosis. Preventive therapy may help prevent progression of tuberculosis infection to disease. OBJECTIVES: The objective of this review was to assess the effects of preventive therapy with anti-tuberculosis drugs in people with HIV infection. SEARCH STRATEGY: The Cochrane Infectious Diseases Group trials register, the Cochrane Controlled Trials Register, Medline (...) , Embase and reference lists of articles were searched. Researchers in the field were contacted. SELECTION CRITERIA: Randomised trials of anti-tuberculosis drugs in people with HIV infection but without evidence of active tuberculosis. DATA COLLECTION AND ANALYSIS: One reviewer assessed eligibility and trial quality. Study authors were contacted for additional information. MAIN RESULTS: Six trials were included. Compared to placebo, preventive therapy was associated with a lower incidence of active

Cochrane2000

540. Mycobacterium vaccae immunotherapy for treating tuberculosis.

Mycobacterium vaccae immunotherapy for treating tuberculosis. BACKGROUND: Mycobacterium vaccae has been advocated for immunotherapy in the treatment of tuberculosis and other infections caused by mycobacteria. OBJECTIVES: The objective of this review was to assess the effects of Mycobacterium vaccae for treating tuberculosis. SEARCH STRATEGY: We searched the Cochrane Infectious Diseases Group trials register, the Cochrane Controlled Trials register, Medline, Embase and reference lists (...) of articles. We also contacted organisations and individuals working in the field. SELECTION CRITERIA: Randomised and quasi-randomised trials of preparations of whole, killed Mycobacterium vaccae in patients with tuberculosis. DATA COLLECTION AND ANALYSIS: One reviewer assessed trial quality and extracted data. MAIN RESULTS: Four trials met the inclusion criteria. There was no effect on mortality (2 trials, RR 1.01, 95% CI 0.50 to 2.04); no consistent effect on sputum negativity or sputum culture

Cochrane2000